$CDTAug 25, 2026, 9:00 AMAI processed
CDT invests in Pep’d via SAFE with $10M valuation cap
AI Summary
CDT Equity (NASDAQ: CDT) entered into a SAFE with Pep’d Inc. that will automatically convert into Safe Preferred Stock upon Pep’d closing an equity financing, subject to a $10 million valuation cap. CDT says the deal gives it capital-efficient exposure to the growing US peptide market and to Pep’d's AI-enabled, telehealth-integrated peptide platform, which has launched and begun generating revenue. Pep’d is controlled by CDT CEO Dr. Andrew Regan, creating a potential conflict of interest, and the release does not disclose the SAFE amount or timing of conversion.
Positives
- SAFE converts to preferred stock on Pep’d equity financing with a $10M valuation cap
- Pep’d has launched its telehealth/peptide platform and has begun generating revenue
- Deal aligns with CDT’s AI-enabled, peptide-focused strategy and is positioned as a capital-efficient exposure
Negatives
- Pep’d is controlled by CDT CEO Dr. Andrew Regan, creating a potential conflict of interest
- SAFE conversion is contingent on Pep’d completing an equity financing, timing uncertain
- Press release does not disclose the size of CDT’s SAFE investment or other financial terms